Green hydrogen production

Search documents
The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film
Globenewswire· 2025-08-27 05:45
Group Performance - The Agfa-Gevaert Group reported a revenue of €281 million in Q2 2025, a decrease of 1.6% compared to €286 million in Q2 2024. For H1 2025, revenue was €523 million, down 2.4% from €536 million in H1 2024 [7][30] - The Group's gross profit decreased to €85 million in Q2 2025, down 10.9% from €96 million in Q2 2024, resulting in a gross profit margin of 30.4% [7][30] - Adjusted EBITDA fell to €13 million in Q2 2025, a decline of 41.2% from €22 million in Q2 2024, with a margin of 4.7% [7][30] HealthCare IT Division - The HealthCare IT division achieved a revenue of €61 million in Q2 2025, reflecting a growth of 4.8% from €58 million in Q2 2024. For H1 2025, revenue increased by 8.2% to €118 million [11][14] - Adjusted EBITDA for HealthCare IT rose significantly by 57.3% to €8.9 million in Q2 2025, compared to €5.6 million in Q2 2024, with a margin of 14.6% [11][20] - The division's strong performance was attributed to the successful transition to cloud-based solutions, particularly in North America, with a stable order intake of €151 million over the past 12 months [14][20] Digital Print & Chemicals Division - The Digital Print & Chemicals division reported a revenue increase of 6.1% to €118 million in Q2 2025, driven mainly by Specialty Films & Chemicals [15][21] - Adjusted EBITDA decreased to €10 million, down 14.0% from €11.6 million in Q2 2024, with a margin of 8.4% [15][21] - The division faced challenges due to unfavorable market conditions affecting profitability, despite maintaining a stable order book [21] Radiology Solutions Division - The Radiology Solutions division experienced a significant revenue decline of 18.4% to €80 million in Q2 2025, heavily impacted by the ongoing decline in the medical film market, particularly in China [18][26] - Adjusted EBITDA for this division was negative at -€4.9 million, compared to a positive €7.1 million in Q2 2024, indicating severe profitability challenges [18][26] - The company is implementing a cost optimization plan for traditional film activities, with expected savings to begin in the second half of 2025 [26] Financial Position and Outlook - The company secured a new revolving credit facility of €180 million, enhancing its financial stability [4][8] - The net profit for Q2 2025 was reported at €30 million, significantly influenced by a favorable arbitration award related to AgfaPhoto [8][30] - The outlook for 2025 anticipates a positive net cash flow, primarily driven by inflows from discontinued operations and legal settlements [10][30]
The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline
Globenewswire· 2025-05-14 05:45
Core Insights - The Agfa-Gevaert Group reported stable adjusted EBITDA in Q1 2025 compared to Q1 2024, with improved sales mix and effective cost control offsetting declines in traditional film markets [1][5][10]. Financial Performance - Total revenue decreased by 3.2% from €250 million in Q1 2024 to €242 million in Q1 2025 [4][10]. - Adjusted EBITDA remained stable at €2 million, representing 0.9% of revenue, up from 0.7% in Q1 2024 [4][10]. - The net loss for the period was €20 million, slightly improved from a loss of €21 million in Q1 2024 [4][10]. Division Performance HealthCare IT - Revenue increased by 12.0% to €57 million, with adjusted EBITDA rising from €1.3 million to €5.0 million [2][9]. - The division saw a 63% increase in rolling order intake over 12 months, with a significant share from new customers and cloud-related contracts [11]. - Gross profit margin improved from 43.8% to 47.9% [11]. Digital Print & Chemicals - Revenue grew by 5.8% to €97 million, with adjusted EBITDA increasing from €1.0 million to €2.3 million [13][17]. - Ink sales rose by 16%, although equipment sales were affected by a weaker investment climate [17]. Radiology Solutions - Revenue declined by 15.6% to €73 million, with adjusted EBITDA dropping to -€4.5 million [15][16]. - The division faced challenges due to a significant decline in medical film markets, particularly in China [5][10]. Contractor Operations - Revenue decreased by 29.1% to €15 million, with adjusted EBITDA down by 30.6% [18]. Outlook - The company expects continued strong performance from growth engines in 2025, with a stronger second half anticipated due to seasonal factors [8][10]. - Cost optimization measures for traditional film activities are expected to yield initial savings in the second half of 2025 [1][5].